

DAFTAR PUSTAKA

1. Reger, M., Welsh, R., Razani, J., Martin, D. J., & Boone KB. A meta-analysis of the neuropsychological sequelae of HIV infection. *J Int Neuropsychol Soc JINS*. 2002;8(3):410–424.
2. Muñoz-Moreno J, Prats A, Pérez-Álvarez N, Fumaz C, Garolera M, Doval E, et al. A Brief and Feasible Paper-Based Method to Screen for Neurocognitive Impairment in HIV-Infected Patients. Vol. 5, *Journal of acquired immune deficiency syndromes*. 2013. 592 p.
3. Nasronudin. Dasar Virologi dan Infeksi HIV. Dalam: *HIV & AIDS Pendekatan Biologi Molekuler, Klinis, dan Sosial*. Kedua. Jusuf Barakbah, Eddy Soewandojo, Suharto, Usman Hadi, Wahyu Dwi Astuti, Bramantono, M.Vitanata Arfijanto, Erwin Astha Trijono, Purwati MR, editor. Surabaya: Airlangga University Press; 2014.
4. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. *J Neurovirol*. 2011;17(1):3–16.
5. Robertson K et al. The prevalence and incidence of neurocognitive impairment in the HAART. *Aids*. 2016;21(November 2006):1915–21.
6. Hoare J, Fouche J-P, Spottiswoode B, Joska J a, Schoeman R, Stein DJ, et al. White matter correlates of apathy in HIV-positive subjects: a diffusion tensor imaging study. *J Neuropsychiatry Clin Neurosci*. 2010;22:313–20.
7. Khoury MN, Tan CS, Peaslee M, Koralnik IJ. CSF viral escape in a patient with HIV-associated neurocognitive disorder. *J Neurovirol*. 2013;19(4):402–5.
8. Solomon TM, Halkitis PN. Cognitive executive functioning in relation to HIV

- medication adherence among gay, bisexual, and other men who have sex with men. *AIDS Behav.* 2008;12(1):68–77.
9. Pastor L, Casellas A, Rupérez M, Carrillo, J, Maculuve S, Jairoce C, et al. IP-10 as a Screening Tool to Optimize HIV Viral Load Monitoring in Resource-limited Settings (article in press). *Clin Infect Dis* . 2017;(2):cix600.
 10. Lane BR, King SR, Bock PJ, Strieter RM, Coffey MJ, Markovitz DM. The C-X-C chemokine IP-10 stimulates HIV-1 replication. *Virology.* 2003;307(1):122–34.
 11. Valverde-Villegas JM, de Medeiros RM, Ellwanger JH, Santos BR, Melo MG de, Almeida SE de M, et al. High CXCL10/IP-10 levels are a hallmark in the clinical evolution of the HIV infection. *Infect Genet Evol* . 2018;57(September 2017):51–8. Available from: <https://doi.org/10.1016/j.meegid.2017.11.002>
 12. Cohen RA, Monte S De, Gongvatana A, Ombao H, Gonzalez B, Devlin KN, et al. Plasma cytokine concentrations associated with HIV/Hepatitis C coinfection are related to attention, executive and psychomotor functioning. 2012;233:204–10.
 13. Sui Y, Potula R, Dhillon N, Pinson D, Li S, Nath A, et al. Neuronal Apoptosis Is Mediated by CXCL10 Overexpression in Simian Human Immunodeficiency Virus Encephalitis. *Am J Pathol* . 2004;164(5):1557–66. Available from: [http://dx.doi.org/10.1016/S0002-9440\(10\)63714-5](http://dx.doi.org/10.1016/S0002-9440(10)63714-5)
 14. Sui Y, Potula R, Dhillon N, Pinson D, Li S, Nath A, et al. Is repetitive opportunistic infection in AIDS patients the effective mechanism for neurodegeneration in terms of endlessly amplifying cytokine/chemokine effect? *Med Hypotheses* . 2004;164(4):587–92.
 15. Rote NS HS. AIDS. In: *Pathophysiology the Biologic for Disease in Adults and Children*. McCance KL, Huether SE, Brashers VL RN, editor. Canada; 2014.

323-333 p.

16. Abbas AK LA. Immunity to viruses. In: Cellular and Molecular Immunology. Philadelphia; 2010. 362-365 p.
17. WHO. Guidelines: The Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. 2013;(Second Edition):129.
18. Kotaki T, Khairunisa SQ, Witaningrum AM, M MQY, Sukartiningrum SD, Diansyah MN, et al. HIV-1 transmitted drug resistance mutations among antiretroviral therapy-Naïve individuals in Surabaya, Indonesia. *AIDS Res Ther* . 2015 Feb 22;12:5.
19. Dolin R, Masur H, Saag M. *AIDS Therapy*. Third. Philadelphia: Elsevier Inc.; 2008.
20. Abbas A, Lichtman A. Immunity to viruses. In: Cellular and Molecular Immunology. Philadelphia: International Edition; 2010. 362-365 p.
21. DEPKES. *Pedoman Nasional Terapi Antiretroviral*. Jakarta; 2004.
22. Murdoch DM, Venter WDF, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): Review of common infectious manifestations and treatment options. *AIDS Res Ther*. 2007;4:1–10.
23. Mehla R. Chemokine Dereglulation in HIV Infection: Role of Interferon Gamma Induced Th1-Chemokine Signaling. *J Clin Cell Immunol* . 2013;04(01).
24. Luster AD, Ravetch J V. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). *J Exp Med* . 1987;166(4):1084–97. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2443596>
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2188708>
25. Schneider D, Ganesan S, Comstock AT, Meldrum CA, Mahidhara R, Goldsmith

- AM, et al. Increased cytokine response of rhinovirus-infected airway epithelial cells in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2010;182(3):332–40.
26. Falconer K, Askarieh G, Weis N, Hellstrand K, Alaeus A, Lagging M. IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV. *Scand J Infect Dis*. 2010;42(11–12):896–901.
 27. Dyer KD, Percopo CM, Fischer ER, Gabryszewski SJ, Rosenberg HF. Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. *Blood*. 2009;114(13):2649–56.
 28. Ip PP, Liao F. Resistance to Dengue Virus Infection in Mice Is Potentiated by CXCL10 and Is Independent of CXCL10-Mediated Leukocyte Recruitment. *J Immunol* . 2010;184(10):5705–14.
 29. Dysfunction T, Brainard DM, Tager AM, Misdraji J, Frahm N, Lichterfeld M, et al. Decreased CXCR3 α CD8 T Cells in Advanced Human Immunodeficiency Virus Infection Suggest that a Homing Defect Contributes to Cytotoxic. 2007;81(16):8439–50.
 30. Wang YA, Yu X, Silverman PM, Harris RL, Edward H. Chemokines and chemokine receptors: Standing at the crossroads of immunobiology and neurobiology. 2010;385(1):22–9.
 31. Kutsch O, Oh J-W, Nath A, Benveniste EN. Induction of the Chemokines Interleukin-8 and IP-10 by Human Immunodeficiency Virus Type 1 Tat in Astrocytes. *J Virol* . 2000;74(19):9214–21.
 32. Asensio RIEC, Maier J, Milner R, Boztug K, Kincaid C, Moulard M, et al. Interferon-Independent , Human Immunodeficiency Virus Type 1 gp120-Mediated Induction of CXCL10 / IP-10 Gene Expression by Astrocytes In Vivo

- and In Vitro †. *Society*. 2001;75(15):7067–77.
33. Van Marle G, Henry S, Todoruk T, Sullivan A, Silva C, Rourke SB, et al. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: A neurotoxic role for IP-10. *Virology*. 2004;329(2):302–18.
 34. Yuan L, Liu A, Qiao L, Sheng B, Xu M, Li W, et al. The relationship of CSF and plasma cytokine levels in HIV infected patients with neurocognitive impairment. *Biomed Res Int*. 2015;2015:6–11.
 35. Schneider D, Ganesan S, Comstock AT, Meldrum CA, Mahidhara R, Goldsmith AM, et al. Increased Cytokine Response of Rhinovirus-infected Airway Epithelial Cells in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* . 2010 Aug 1;182(3):332–40.
 36. Dyer KD, Percopo CM, Fischer ER, Gabryszewski SJ, Rosenberg HF. Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. *Blood* . 2009 Sep 24;114(13):2649–56.
 37. Mihm S, Schweyer S, Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN- γ and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. *J Med Virol* . 2003;70(4):562–70.
 38. Nightingale ZD, Patkar C, Rothman AL. Viral replication and paracrine effects result in distinct, functional responses of dendritic cells following infection with dengue 2 virus. *J Leukoc Biol* . 2008 Oct 23;84(4):1028–38.
 39. Covaleda L, Fuller FJ, Payne SL. EIAV S2 enhances pro-inflammatory cytokine and chemokine response in infected macrophages. *Virology* . 2010 Feb 5;397(1):217.
 40. Hsieh Y-H, Chen CWS, Schmitz S-FH, King C-C, Chen W-J, Wu Y-C, et al.

- Candidate genes associated with susceptibility for SARS-coronavirus. *Bull Math Biol.* 2010;72(1):122–32.
41. Sin J-I, Kim JJ, Pachuk C, Satishchandran C, Weiner DB. DNA Vaccines Encoding Interleukin-8 and RANTES Enhance Antigen-Specific Th1-Type CD4(+) T-Cell-Mediated Protective Immunity against Herpes Simplex Virus Type 2 In Vivo. *J Virol* . 2000 Dec 3;74(23):11173–80. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC113206/>
 42. Lam CWK, Chan MHM, Wong CK. Severe Acute Respiratory Syndrome: Clinical and Laboratory Manifestations. *Clin Biochem Rev* . 2004 May;25(2):121–32.
 43. Stylianou E, Aukrust P, Bendtzen K, Müller F, Frøland SS. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)—possible immunosuppressive role of IFN- α in HIV infection. *Clin Exp Immunol* . 2000 Mar 3;119(3):479–85.
 44. Crisan D, Grigorescu MD, Radu C, Suciuc A, Grigorescu M. Interferon- γ -inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response. *Indian J Med Res* . 2017 Apr 20;145(4):543–50.
 45. Salvatore CM, Techasaensiri C, Tagliabue C, Katz K, Leos N, Gomez AM, et al. Tigecycline Therapy Significantly Reduces the Concentrations of Inflammatory Pulmonary Cytokines and Chemokines in a Murine Model of *Mycoplasma pneumoniae* Pneumonia . *Antimicrob Agents Chemother* . 2009 Apr 12;53(4):1546–51.
 46. Lettinga K, Weijer S, Speelman P, Prins J, van der Poll T, Verbon A. Reduced interferon- γ release in patients recovered from Legionnaires' disease. *Thorax* . 2003 Jan;58(1):63–7.

47. Biraro IA, Kimuda S, Egesa M, Cose S, Webb EL, Joloba M, et al. The Use of Interferon Gamma Inducible Protein 10 as a Potential Biomarker in the Diagnosis of Latent Tuberculosis Infection in Uganda. Delogu G, editor. PLoS One . 2016 Jan 15;11(1):e0146098.
48. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with *M. tuberculosis* in a whole blood based T-cell assay. BMC Res Notes . 2009 Feb 4;2:19.
49. Shiraki Y, Ishibashi Y, Hiruma M, Nishikawa A, Ikeda S. *Candida albicans* abrogates the expression of interferon-gamma-inducible protein-10 in human keratinocytes. FEMS Immunol Med Microbiol. 2008;54(1):122–8.
50. Wang H-C, Dann SM, Okhuysen PC, Lewis DE, Chappell CL, Adler DG, et al. High Levels of CXCL10 Are Produced by Intestinal Epithelial Cells in AIDS Patients with Active Cryptosporidiosis but Not after Reconstitution of Immunity . Infect Immun . 2007 Jan 16;75(1):481–7.
51. Amin DN, Ngoyi DM, Nkhwachi G-M, Palomba M, Rottenberg M, Büscher P, et al. Identification of Stage Biomarkers for Human African Trypanosomiasis. Am J Trop Med Hyg . 2010 Jun 18;82(6):983–90.
52. Jain V, Armah HB, Tongren JE, Ned RM, Wilson NO, Crawford S, et al. Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India. Malar J . 2008 May 19;7:83.
53. Vasquez RE, Xin L, Soong L. Effects of CXCL10 on Dendritic Cell and CD4(+) T-Cell Functions during *Leishmania amazonensis* Infection . Infect Immun . 2008 Jan 12;76(1):161–9.
54. Elbirt D, Mahlab-Guri K, Bezalel-Rosenberg S, Gill H, Attali M, Asher I. HIV-associated neurocognitive disorders (HAND). Isr Med Assoc J . 2015;17(1):54–

9.

55. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. 2015;69(18):1789–99.
56. Zayyad Z, Spudich S. Neuropathogenesis of HIV: From Initial Neuroinvasion to HIV Associated Neurocognitive Disorder (HAND). *Curr HIV/AIDS Rep* . 2015 Mar;12(1):16–24.
57. Lamers SL, Fogel GB, Nolan DJ, McGrath MS, Salemi M. HIV-Associated Neuropathogenesis: A Systems Biology Perspective for Modeling and Therapy. *Biosystems* . 2014 May 13;119:53–61.
58. Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, et al. HIV-associated neurocognitive disorder - Pathogenesis and prospects for treatment. *Nat Rev Neurol* . 2016;12(4):234–48.
59. Saxena A, Khosraviani S, Noel S, Mohan D, Donner T, Hamad ARA. The effects of anti-retroviral treatment initiation on cognition in HIV-infected individuals with advanced disease in Pune, India. 2016;74(1):27–34.
60. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Et. Al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV- infected patients. *Neurology*. 2011;76:1403–9.
61. C. Pinnetti, P. Balestra, R. Libertone, P. Lorenzini, A. Cozzi-Lepri, A. Ammassari, M. Ricottini, M. Plazzi, S. Menichetti, V. Tozzi AA. Use of efavirenz is not associated to an increased risk of neurocognitive impairment in HIV-infected patients. 2014;
62. Vance DE, McDougall GJ, Wilson N, Debiasi MO, Cody SL. Cognitive consequences of aging with HIV: Implications for neuroplasticity and

- rehabilitation. *Top Geriatr Rehabil*. 2014;30(1):35–45.
63. Vermund SH. Global HIV Epidemiology: A Guide for Strategies in Prevention and Care. *Curr HIV/AIDS Rep* . 2014 Jun;11(2):93–8.
 64. Detels R, Jacobson L, Margolick J, Martinez-Maza O, Muñoz A, Phair J, et al. The multicenter AIDS Cohort Study, 1983 to *Public Health* . 2012 Mar 27;126(3):196–8.
 65. Cross S, Önen N, Gase A, Overton ET, Ances BM. Identifying Risk Factors for HIV-Associated Neurocognitive Disorders Using the International HIV Dementia Scale. *J Neuroimmune Pharmacol* . 2013 Dec 10;8(5):1114–22.
 66. Gilmore JH. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. *North*. 2008;29(10):1883–9.
 67. Subica AM, Fowler JC, Elhai JD, Frueh BC, Sharp C, Kelly L, et al. Psychological Assessment Factor Structure and Diagnostic Validity of the Beck Depression Inventory – II With Adult Clinical Inpatients : Comparison to a Gold-Standard Diagnostic Interview Factor Structure and Diagnostic Validity of the Beck Depression Inv. 2014;26(4):1106–15.
 68. Marcotte TD, Deutsch R, McCutchan JA, Moore DJ, Letendre S, Ellis RJ, et al. Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. *Arch Neurol*. 2003;60(10):1406–12.
 69. McCutchan JA, Marquie-Beck JA, FitzSimons CA, Letendre SL, Ellis RJ, Heaton RK, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. *Neurology*. 2012;78(7):485–92.
 70. Becker JT, Kingsley L, Mullen J, Cohen B, Sacktor N. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. *Neurology* . 2009;73(16):1292–9.

71. Heaton R, Franklin D, Letendre S, Ellis R, Fennema-Notestine C, Vaida F, Smith D, Collier A, Marra C, Clifford D, Gelman B, McArthur J, Morgello S, Simpson D, McCutchan A GI. Aging amplifies HIV neurocognitive impairment: The effects may be related to vascular and metabolic factors. *J Neurovirol.* 2012;18(Suppl 1):S46.
72. Tedaldi EM, Minniti NL, Fischer T. HIV-associated neurocognitive disorders: The relationship of Hiv infection with physical and social comorbidities. Vol. 2015, *BioMed Research International.* 2015.
73. Okafor CN, Kelso NE, Bryant V, Burrell LE, Míguez MJ, Gongvatana A, et al. Body Mass Index, Inflammatory Biomarkers and Neurocognitive Impairment in HIV-Infected Persons. *Psychol Health Med.* 2017 Mar 20;22(3):289–302.
74. Suemoto CK, Gilsanz P, Mayeda ER, Glymour MM. Body mass index and cognitive function: the potential for reverse causation. *Int J Obes (Lond).* 2015 Sep 8;39(9):1383–9.
75. Bowie CR, Harvey PD. Administration and interpretation of the Trail Making Test. *Nat Protoc.* 2006;1(5):2277–81.
76. Kamminga J, Cysique LA, Lu G, Batchelor J, Brew BJ. Validity of cognitive screens for HIV-associated neurocognitive disorder: A systematic review and an informed screen selection guide. *Curr HIV/AIDS Rep.* 2013;10(4):342–55.
77. Reitan R. Trail Making Test TMT. *Adjut Gen Off War Dep US Army.* 1944;
78. Salthouse TA. What cognitive abilities are involved in trail-making performance? *Intelligence.* 2011;39(4):222–32.
79. Dobbs BM, Shergill SS. How effective is the Trail Making Test (Parts A and B) in identifying cognitively impaired drivers? *Age Ageing.* 2013 Sep 1;42(5):577–81.

80. Punyadeera C, Schneider EM, Schaffer D, Hsu H-Y, Joos TO, Kriebel F, et al. A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. *J Emergencies, Trauma Shock* . 2010 Jan 26;3(1):26–35.
81. Dahlan MS. *Besar Sampel dalam Penelitian Kedokteran dan Kesehatan*. 4th ed. Jakarta: Epidemiologi Indonesia; 2014. 71 p.
82. Halfaker DA, Akeson ST, Hathcock DR, Mattson C, Wunderlich TL. 3 - Psychological Aspects of Pain. In: Lennard TA, Walkowski S, Singla AK, Vivian DGBT-PP in CP (Third E, editors. Saint Louis: Hanley & Belfus; 2011. p. 13–22.
83. Comstedt P, Storgaard M, Lassen AT. The Systemic Inflammatory Response Syndrome (SIRS) in acutely hospitalised medical patients: a cohort study. *Scand J Trauma Resusc Emerg Med* . 2009 Dec 27;17:67.
84. Ditjen PP & PL Kemenkes RI, Kementrian Kesehatan RI. *Data Statistik HIV di Indonesia 2014*. Kemenkes RI. 2014. p. 1–3.
85. Muñoz moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negro E, Garolera M, et al. Nadir CD4 Cell Count Predicts Neurocognitive Impairment in HIV-Infected Patients. 2008;24(10).
86. Men H, Kissel EC, Pukay-martin ND, Bornstein RA, Ph D. Between Age and Cognitive Function in. *J Neuropsychiatry Clin Neurosci*. 2005;17(2):180–4.
87. Solís-ortiz S, Gutiérrez-muñoz M, Morado-crespo L, Trejo-bahena SA, Kala L. Executive Functions Correlated with Body Mass Index in Overweight Middle-Aged Women. 2016;(March):410–7.
88. Stern Y, P McDermott M, Albert S, Palumbo D, A Selnes O, Mcarthur J, et al. Factors associated with incident human immunodeficiency virus-dementia. Vol.

- 58, Archives of neurology. 2001. 473-479 p.
89. Rosenberg M, Pettifor A, Duta M, Demeyere N, Wagner G, Selin A, et al. Executive function associated with sexual risk in young South African women : Findings from the HPTN 068 cohort. 2018;1-14.
 90. Oosterman JM, de Vries K, Scherder EJA. Executive ability in relation to blood pressure in residents of homes for the elderly. Arch Clin Neuropsychol. 2007;22(6):731-8.
 91. Podraza AM, Bornstein RA, Para MF, Para MF, Fass RJ, Rice RR, et al. Neuropsychological Performance and CD4 Levels in HIV-1 Asymptomatic Infection*. J Clin Exp Neuropsychol. 1994;16(5):777-83.